Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Nystatin Cream

×

Overview

What is Nystatin Cream?

Nystatin is a polyene antifungal antibiotic obtained from

Structural formula:

C H NO Molecular Weight: 926.13

Nystatin cream is for dermatologic use.

Each gram contains 100,000 USP Nystatin Units in an aqueous, cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid and potassium sorbate.



What does Nystatin Cream look like?



What are the available doses of Nystatin Cream?

Sorry No records found.

What should I talk to my health care provider before I take Nystatin Cream?

Sorry No records found

How should I use Nystatin Cream?

Nystatin cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by and other susceptible species.

Adults and Pediatric Patients (Neonates and Older)


What interacts with Nystatin Cream?

Sorry No Records found


What are the warnings of Nystatin Cream?

Sorry No Records found


What are the precautions of Nystatin Cream?

Sorry No Records found


What are the side effects of Nystatin Cream?

Sorry No records found


What should I look out for while using Nystatin Cream?

Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.


What might happen if I take too much Nystatin Cream?

Sorry No Records found


How should I store and handle Nystatin Cream?

Store vial in its lead shield at a temperature of 5°-30°C, 41°-86°F. Do not freeze.Nystatin Cream USP is a light yellow to yellow cream that is supplied in: 15 gram tube NDC 0316-0221-15 30 gram tube NDC 0316-0221-30 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.Crown Laboratories, Inc., Johnson City, TN 37604Printed in USAP9526.00Nystatin Cream USP is a light yellow to yellow cream that is supplied in: 15 gram tube NDC 0316-0221-15 30 gram tube NDC 0316-0221-30 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.Crown Laboratories, Inc., Johnson City, TN 37604Printed in USAP9526.00Nystatin Cream USP is a light yellow to yellow cream that is supplied in: 15 gram tube NDC 0316-0221-15 30 gram tube NDC 0316-0221-30 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.Crown Laboratories, Inc., Johnson City, TN 37604Printed in USAP9526.00Nystatin Cream USP is a light yellow to yellow cream that is supplied in: 15 gram tube NDC 0316-0221-15 30 gram tube NDC 0316-0221-30 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.Crown Laboratories, Inc., Johnson City, TN 37604Printed in USAP9526.00Nystatin Cream USP is a light yellow to yellow cream that is supplied in: 15 gram tube NDC 0316-0221-15 30 gram tube NDC 0316-0221-30 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.Crown Laboratories, Inc., Johnson City, TN 37604Printed in USAP9526.00


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Pharmacokinetics

Nystatin is not absorbed from intact skin or mucous membrane.

Non-Clinical Toxicology
Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for loss of control.

An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore concomitant administration of glyburide tablets (micronized) and bosentan is contraindicated.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glyburide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for hypoglycemia.

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism of action for this interaction is not known.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

General Nystatin cream should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

The frequency of adverse events reported in patients using nystatin cream is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See .)

To report SUSPECTED ADVERSE REACTIONS, contact Crown Laboratories, Inc. at 1-423-926-4413 or FDA at 1-800-FDA-1088 or https://www.fda.gov/Safety/MedWatch/

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).